-
公开(公告)号：US20240376221A1
公开(公告)日：2024-11-14
申请号：US18660672
申请日：2024-05-10
Applicant: Genmab A/S , BioNTech SE
Inventor： Kristel Kemper , Maarten van der Kroef , Dennis Verzijl , Andrea Gorlani , Pauline Linda de Goeje , Lars Guelen , David Satijn , Esther C. W. Breij , Ugur Sahin , Sina Fellermeier-Kopf , Maren Köhne
Abstract: The present invention relates to antibodies capable of binding to human OX40 and to variants thereof comprising a modified Fc region comprising at least one mutation that enhances the Fc-Fc interaction of the antibody and at least one mutation that reduces the Fc effector functions of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
-
公开(公告)号：US20240339174A1
公开(公告)日：2024-10-10
申请号：US18289425
申请日：2022-05-04
Applicant: BioNTech SE , InstaDeep Ltd.
Inventor： Alexander Muik , Asaf Poran , Yunpeng Liu , Ugur Sahin , Karim Beguir , Marcin Skwark , Thomas Pierrot , Yunguan Fu
IPC: G16B20/20 , C07K14/005 , G16B15/30 , G16B40/20
CPC classification number: G16B20/20 , C07K14/005 , G16B15/30 , G16B40/20 , C12N2770/20022
Abstract: The present disclosure provides technologies for identifying, characterizing, and/or monitoring sequences of a variant of a reference infectious agent (e.g., but not limited to viral variants, for example in some embodiments SARS-CoV-2 variants) for transmissibility factors and/or immune escape potential, and/or for detecting and/or monitoring variants in environmental or biological samples, and/or for designing, preparing, and/or administering vaccines for such variants.
-
公开(公告)号：US12077596B2
公开(公告)日：2024-09-03
申请号：US17360438
申请日：2021-06-28
Applicant: GENMAB A/S , BioNTech SE
Inventor： Isil Altintas , David Satijn , Rik Rademaker , Paul Parren , Friederike Gieseke , Ugur Sahin
IPC: C07K16/28 , A61K39/395 , G01N33/569
CPC classification number: C07K16/2878 , A61K39/3955 , G01N33/56972 , C07K2317/24 , C07K2317/31 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/565 , C07K2317/92
Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
-
公开(公告)号：US20240269321A1
公开(公告)日：2024-08-15
申请号：US18246533
申请日：2021-09-30
Applicant: BioNTech SE
Inventor： Heinrich HAAS , Sebastian HÖRNER , Thomas Michael HILLER , Tobias KIND , Tijana BACIC
CPC classification number: A61K48/0033 , A61K47/26 , A61K47/543 , A61K47/547 , A61K47/548 , A61K47/6911
Abstract: The present disclosure relates to methods for preparing RNA lipoplex particles for delivery of RNA to target tissues after parenteral administration, in particular after intravenous administration, and compositions comprising such RNA lipoplex particles. The present disclosure also relates to methods which allow preparing RNA lipoplex particles in an industrial GMP-compliant manner. Furthermore, the present disclosure relates to methods and compositions for storing RNA lipoplex particles without substantial loss of the product quality and, in particular, without substantial loss of RNA activity.
-
公开(公告)号：US20240269040A1
公开(公告)日：2024-08-15
申请号：US18563738
申请日：2022-05-25
Applicant: BioNTech SE
Inventor： Ferdia Bates , Karina Nawrath , Christian Panhans , Marco Prehn , Ralph Krause , Christian Friebe , Moritz Kuhn , Frank Schoepe , Thomas Oppelt
Abstract: A device (100) for accelerating thawing of a content of one or a plurality of containers (160) is provided and an associated method.
-
Patent Agency Ranking
公开(公告)号：US20240262924A1
公开(公告)日：2024-08-08
申请号：US18570257
申请日：2022-06-20
Applicant: GENMAB A/S , BioNTech SE
Inventor： Ugur SAHIN , Alexander MUIK , Ulf FORSSMANN , Maria N. JURE-KUNKEL , Gaurav BAJAJ , Craig THALHAUSER , Nora PENCHEVA
CPC classification number: C07K16/2878 , A61P35/00 , C07K16/2827 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/31
Abstract: The present invention relates to a method for reducing or preventing progression of a tumor or treating cancer in a subject, comprising administering to the subject a binding agent comprising a first antigen-binding region binding to human CD137, and a second antigen-binding region binding to human PD-L1. The invention further provides a binding agent for use in reducing or preventing progression of a tumor or for use in treatment of cancer.
-
公开(公告)号：US11939388B2
公开(公告)日：2024-03-26
申请号：US17360437
申请日：2021-06-28
Applicant: GENMAB A/S , BioNTech SE
Inventor： Isil Altintas , David Satijn , Rik Rademaker , Paul Parren , Friederike Gieseke , Ugur Sahin
IPC: C07K16/28 , A61K39/395 , G01N33/569
CPC classification number: C07K16/2878 , A61K39/3955 , G01N33/56972 , C07K2317/24 , C07K2317/31 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/565 , C07K2317/92
Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
-
公开(公告)号：US20240042011A1
公开(公告)日：2024-02-08
申请号：US18186914
申请日：2023-03-20
Applicant: BioNTech SE
Inventor： Alexander Muik , Asaf Poran , Kena Anne Swanson , Qi Yang , Hui Cai , Ugur Sahin
IPC: A61K39/215 , A61K39/145 , A61K9/127 , A61K47/26 , C12N15/86
CPC classification number: A61K39/215 , A61K39/145 , A61K2039/545 , A61K47/26 , C12N15/86 , A61K9/1272
Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
-
79.发明公开公开(公告)号：US20240033344A1
公开(公告)日：2024-02-01
申请号：US18036681
申请日：2021-11-15
Applicant: BioNTech SE
Inventor： Heinrich Haas , Kaushik Thanki , Isaac Hernan Esparza Borquez , Sebastian Hörner , Bulat Sydykov , Martin Kapp
IPC: A61K39/215 , A61K47/26 , A61K9/51 , A61K9/19
CPC classification number: A61K39/215 , A61K47/26 , A61K9/5123 , A61K9/5192 , A61K9/19 , A61K2039/55555
Abstract: The present disclosure relates generally to the field of pharmaceutical compositions comprising particles, in particular lipid nanoparticles (LNPs), and mRNA, methods for preparing and storing such pharmaceutical compositions, and the use of pharmaceutical compositions in therapy.
-
公开(公告)号：US20240009238A1
公开(公告)日：2024-01-11
申请号：US18044955
申请日：2021-09-14
Applicant: BioNTech SE
Inventor： Ugur SAHIN , Joycelyn WÜSTEHUBE-LAUSCH , Hans-Ulrich SCHMOLDT
IPC: A61K35/17 , C07K16/28 , C12N5/0783 , A61K39/00 , A61P35/00
CPC classification number: A61K35/17 , C07K16/28 , C12N5/0636 , A61K39/4633 , A61K39/4611 , A61P35/00 , A61K39/464402 , A61K2239/13
Abstract: The invention relates to agents and methods for targeted delivery of payloads to cells. The agents and methods are useful for delivering therapeutic or diagnostic agents to target cells. In one embodiment, the invention involves administering RNA encoding a peptide or polypeptide (docketing compound) comprising a binding moiety (primary targeting moiety) binding to target cells and a further binding moiety (secondary target) binding to an agent that comprises a payload (effector probe). Following expression of the RNA, the primary targeting moiety may bind to a target antigen such as a cancer antigen on cancer cells and then a secondary targeting moiety comprised in the effector probe may target the secondary target to thereby precisely deliver a “payload” to the target cells such as cancer cells.
-
-
-
-
-
-
-
-
-
Search Results
161
records
(took 0.022 seconds)
